Introduction {#Sec1}
============

Cancer is a major public health problem around the globe^[@CR1]^. It is currently the second leading cause of death, and approximately 1, 658, 370 new cancer cases worldwide, 429000 new cases in China were reported according to the Cancer Statistics 2015^[@CR2]^. The carcinogenesis is involved in multifactor interaction among environmental exposures, life style and internal factors. In terms of internal factors, the main manifestations are changes in hormone secretion and immune conditions, and genetic variation in the key signaling pathway. In humans, the phosphatase and tensin homolog deleted on chromosome10 (pTEN)/AKT/mammalian target of rapamycin (mTOR) signaling pathway is frequently activated in a variety of cancers, and play a critical role in many cellular processes including proliferation, differentiation, cell cycle progression, cell motility and tumorigenesis, tumor growth, angiogenesis^[@CR3]--[@CR5]^. Therefore, the Single nucleotide polymorphisms (SNPs) of core genes in the pTEN/AKT/mTOR pathway may impact the transcription and expression of the proteins and thus alter the capacity and function of the pathway, which could play a critical role in carcinogenesis^[@CR6]--[@CR9]^.

The mTOR, which is located at the chromosome 1q36.2, plays a significant role in the pTEN/AKT/mTOR pathway. It exerts a prosurvival influence on cells through the activation of factors involved in protein synthesis^[@CR10]--[@CR13]^. *pTEN i*s a tumor suppressor and plasma-membrane lipid phosphatase and which dephosphorylates PIP3 to PIP2, inhibiting the activation of AKT, and negatively regulates the pTEN/AKT/mTOR pathway^[@CR14]^. To date, among the pTEN/AKT/mTOR pathway genes, there are more than 1000 coding-region SNPs (cSNPs) (<http://www.ncbi.nlm.nih.gov/projects/SNP>) reported. Among those cSNPs, a few potential functional SNPs especially located in the 5′-untranslated regions(5′UTR) and 3′UTR of the candidate genes could affect the carcinogenesis by modulating the transcriptional activity of candidate genes or by interacting with the miRNA binding, such as rs2295080 in the *mTOR* gene promoter region^[@CR15]--[@CR23]^, rs2494750 and rs2494752 in the *AKT1* 5′UTR region^[@CR7],[@CR15],[@CR23]--[@CR27]^, rs2536 in the 3′UTR of *mTOR* ^[@CR7],[@CR15]--[@CR18],[@CR22],[@CR23],[@CR28]--[@CR30]^ and rs701848 the *pTEN* 3′UTR region^[@CR7],[@CR15],[@CR27],[@CR31]--[@CR42]^. Furthermore, previous studies demonstrated that the *mTOR* rs2295080 TT genotypes carriers showed a much higher mRNA levels of *mTOR* transcription by increasing the transcriptional activity of *mTOR* gene in human gastric cancer cell line SGC-7901^[@CR6]^. Moreover, carrying the rs2295080 T allele showed increased mTOR mRNA levels compared with the G allele in the patients with renal cell cancer^[@CR7]^ and colorectal cancer^[@CR8]^. Moreover, another SNP rs2536 located in the *mTOR* 3′-UTR was predicted to affect miRNA-binding site activity. Li *et al*.^[@CR43]^ found that co-transfection of the rs2536 A allele and G allele with miR-767-3p exhibited different promoter activities. Additionally, the polymorphism of *pTEN* rs701848 was proposed to involve in affecting the activity of micorRNA binding site^[@CR36]^. Therefore, considering the critical role of the genetic variations in the pTEN/AKT/mTOR pathway, understanding the association between these SNPs and cancer susceptibility are urgently required.

To date, numerous studies have investigated the association of genetic polymorphisms of pTEN/AKT/mTOR pathway genes including rs2295080, rs2536 of *mTOR* gene, rs2494750 and rs2494752 in the *AKT1* gene, *pTEN* rs701848 with cancer susceptibility^[@CR6]--[@CR9],[@CR15]--[@CR23],[@CR28]--[@CR42]^, however, the results were inconclusive. Therefore, this comprehensive meta-analysis was performed in 5 SNPs of pTEN/AKT/mTOR pathway genes included all eligible case-control studies for evaluating the cancer risk and providing more precise estimation of these associations.

Materials and Methods {#Sec2}
=====================

Literature research and data extraction {#Sec3}
---------------------------------------

A comprehensive literature search was performed independently by three authors (Z.Z., J.Z., and Q.C.C.) in five electronic databases: PubMed database, CNKI, CbmWeb, WanFang Date, BIOSIS Preview, and ClinicalKey. All the searched eligible original studies and review articles were reviewed carefully to identify the relevant articles by using the following search terms "*mTOR* rs2295080" or "*mTOR* rs2536" or "*pTEN* rs701848" or "*AKT1* rs2494750" or "*AKT1* rs2494752" and "polymorphism or SNP or single nucleotide polymorphism or variation or mutation" and "cancer or carcinoma or tumor or neoplasm", (the search was updated on Feb 15, 2017). This search was limited to these articles with English or Chinese language, and the results were reviewed and compared by a forth reviewer (Y. L.W.).

In this meta-analysis, selected publications were eligible if they fulfilled the following criteria: (1) a case-control study or cohort study design; (2) evaluated the association of the genetic polymorphisms of *mTOR*, AKT1, and *pTEN* gene with the risk of cancer; (3) sufficient genotypic and/or allelic information for estimating the odds ratio (OR) with 95% confidence intervals (CIs) was provided; (4) the samples size of cases or controls were ≥20. Animal studies, case reports, reviews, and unpublished results were excluded. The following data was extracted from each publication in the collection criterion by Z.Z. and Y. L.W. independently: first author, publication year, ethnicity, country, cancer type, control source (population-based controls, or hospital-based controls), genotyping method, the total number of genotyped cases or controls, and the number of each genotype for cases and controls with each SNP for cancer risk assessment.

Statistical analysis {#Sec4}
--------------------

For the genotype frequency of the controls, the Hardy-Weinberg equilibrium (HWE) was assessed by using the Chi-square test or Fisher's exact test (*P* \> 0.05) in each study. The pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were estimated to evaluate the strength of association between these selected 5 SNPs and cancer risk. The pooled estimated ORs and CIs were determined by *Z*-test based on homozygote model, heterozygote model, dominant model, recessive model, and an additive model(significant for *P* \< 0.05). The heterogeneity between-study was assessed across all eligible comparisons by using χ^2^-based Cochran's Q-test (significant for *P* \< 0.10). The random-effects model (DerSimonian-Laird method) was chosen If there is statistical heterogeneity, otherwise the fixed-effects model (Mantel--Haenszel method) was used if the studies were homogeneous. The *I* ^2^ statistics was also determined from 0% to 100%, which quantified the heterogeneity irrespective of the number of studies. The sensitivity meta-analysis was assessed by leave-one-out each time to reflect the influence of each study to the pooled estimates. The publication bias was evaluated by the Egger's and Begg-Matzumdar linear regression tests using asymmetry of the funnel plot (significant for *P* \< 0.10). All the statistical analyses of this meta-analysis were performed by using Stata 12.0 software (StataCorp LP, College Station, USA) and Open Meta-Analyst (<http://www.cebm.brown.edu/openmeta/>).

Results {#Sec5}
=======

Studies extraction and characteristics {#Sec6}
--------------------------------------

Figure [1](#Fig1){ref-type="fig"} summarizes a flowchart presenting the literature review process of study identification, inclusion, exclusion. With the search strategy, a total of 145 published articles were extracted and identified for cancer risk assessment from PubMed, CNKI, CbmWeb, WanFang Date, BIOSIS Preview. After manually screening abstracts and texts of the included 145 studies, 114 were excluded for 2 lack of enough information, 14 abstracts without sufficient data, and 98 duplicated publication or overlapping with other publications for further evaluation. Finally, 31 studies of Asian population were met the inclusion criteria^[@CR6]--[@CR9],[@CR15]--[@CR23],[@CR28]--[@CR42]^, 13 studies of them evaluated the association of *mTOR* rs2295080 with cancer risks^[@CR6]--[@CR9],[@CR15]--[@CR23]^, 10 studies determined the SNP rs2536 of *mTOR* gene and cancer susceptibility^[@CR7],[@CR15]--[@CR18],[@CR22],[@CR23],[@CR28]--[@CR30]^, 16 publications were *pTEN* rs701848 polymorphism^[@CR7],[@CR15],[@CR27],[@CR31]--[@CR42]^, 6 reports studied the *AKT1* rs2494750 SNP^[@CR7],[@CR15],[@CR23]--[@CR27]^ and 3 reports determined *AKT1* rs2494752 SNP^[@CR19],[@CR26],[@CR27]^. The distribution of genotypes in the controls for the SNPs of pTEN/AKT/mTOR pathway were in the HWE, except for these 2 publications of Liu, B *et al*.^[@CR33]^ for rs70148 and Fallah *et al*.^[@CR24]^ for rs2494750 (Table [1](#Tab1){ref-type="table"}). In this final meta-analysis 8965 cases and 9868 controls for the *mTOR* rs2295080, 8411 cases and 8837 controls for the *mTOR* rs2536, 5882 cases and 6284 controls for the *pTEN* rs701848, 4332 cases and 4498 controls for the *AKT1* rs2494750, and 3187 cases and 3174 controls for the *AKT1* rs2494752 were included. The types of cancers mainly include renal cancer, prostate cancer, acute lymphoblastic leukemia (ALL), gastric cancer, hepatocellular cancer, laryngo cancer, colorectal cancer and esophageal squamous cell cancer (ESCC). The ethnicity of the included studies is Asian, and genotyping method includes TaqMan SNP genotyping assay and PCR-RFLP method. The essential characteristics for all studies were shown in Table [1](#Tab1){ref-type="table"}.Figure 1Flow of identification, inclusion, exclusion of the studies. Table 1Characteristics of studies included in the meta-analysis.VariantAuthor\[ref\]YearCountryEthnicityTumor typeControl SourceGenotyping methodCasesControlsHWE (cases)HWE (controls)***mTOR*** **rs2295080TTTGGGTotalTTTGGGTotal**Cao, Q.^[@CR7]^2012ChinaAsianRenal cancerHBTaqMan assay45421838710438277457600.0840.891Chen, J. W.^[@CR15]^2012ChinaAsianProstate cancerHBTaqMan assay42920928666413259367080.6900.573Huang, L.^[@CR16]^2012ChinaAsianALLHBTaqMan assay25414023417353180215540.5230.742Li, Q. X.^[@CR17]^2013ChinaAsianProstate cancerPBPCR-RFLP6533114010046173825210510.6970.468Xu, M.^[@CR6]^2013ChinaAsianGastric cancerHBPCR-RFLP48224625753497305528540.3450.569Zhu, M. L.^[@CR18]^2015ChinaAsianESCCHBTaqMan assay6743904911137023624911130.4320.788Xu, M.^[@CR8]^2015ChinaAsianColorectal cancerHBTaqMan assay48222530737459273457770.5630.602Wang, M. Y.^[@CR19]^2015ChinaAsianGastric cancerHBTaqMan assay5683944010026073554110030.0050.221Zhao, P.^[@CR20]^2015ChinaAsianALLHBPCR-RFLP685015133173111122960.2210.263Zhao, P.^[@CR20]^2015ChinaAsianAMLHBPCR-RFLP2714647173111122960.0800.263Zhu, J. H.^[@CR21]^2015ChinaAsianRenal cancerHBTaqMan assay6743904911137023624911130.4320.788Zhao, Y.^[@CR22]^2016ChinaAsianBreast cancerHBSequencing35119712560345212265830.0090.358Zhang, J.^[@CR23]^2016ChinaAsianRenal cancerHBTaqMan assay45421838710438277457600.0840.891***mTOR*** **rs2536TTTCCCTotalTTTCCCTotal**Cao, Q.^[@CR7]^2012ChinaAsianRenal cancerHBTaqMan assay60799471062812847600.0010.353Chen, J. W.^[@CR15]^2012ChinaAsianProstate cancerHBTaqMan assay56596566658511947080.6970.435Huang, L.^[@CR16]^2012ChinaAsianALLHBTaqMan assay34665641744810335540.1530.258Li, Q.^[@CR17]^2013ChinaAsianProstate cancerPBPCR-RFLP804192810048941471010510.3460.156Zhu, M. L.^[@CR18]^2013ChinaAsianESCCHBTaqMan assay95116571123957157711210.9570.839Mao, L. Q.^[@CR28]^2013ChinaAsianHepatocellular cancerHBTaqMan assay8491861310488501881410520.4390.330He, J.^[@CR29]^2013ChinaAsianGastric cancerHBTaqMan assay938179811251019170711960.8650.975Liu, Y. C.^[@CR30]^2014ChinaAsianHepatocellular cancerHBTaqMan assay8491861310488501881410520.4390.330Zhang, J.^[@CR23]^2016ChinaAsianRenal cancerHBTaqMan assay60799471062812847600.9870.353Zhao, Y.^[@CR22]^2016ChinaAsianBreast cancerHBSequencing45310075604869345830.5800.845***pTEN*** **rs701848TTTCCCTotalTTTCCCTotal**Zou, J. F.^[@CR31]^2006ChinaAsianLaryngo cancerHBPCR-RFLP172312522852241040.5470.135Liu, B.^[@CR33]^2008ChinaAsianLaryngo cancerHBPCR-RFLP7201291132291040.578**0.008**Zhai, Y.^[@CR32]^2009ChinaAsianLaryngo cancerHBPCR-RFLP29451739265424440.1440.074Song, Z. X.^[@CR34]^2009ChinaAsianLaryngo cancerHBPCR-RFLP4674291492654241040.7910.073Shi, G. L.^[@CR35]^2009ChinaAsianLung cancerHBPCR-RFLP214313772454261040.0260.134Song, Z. X.^[@CR42]^2009ChinaAsianGastric cancerHBPCR-RFLP4367215865116341040.3110.253Ding, J.^[@CR36]^2011ChinaAsianHepatocellular cancerHBPCR-RFLP2223381501312773511322150.7970.788Cao, Q.^[@CR7]^2012ChinaAsianRenal cancerHBTaqMan assay701213571010390337600.0550.691Chen, J. W.^[@CR15]^2012ChinaAsianProstate cancerHBTaqMan assay2123291256662353531207080.7890.956Jang, Y.^[@CR38]^2013ChinaAsianESCCHBPCR-RFLP9115558304183165654130.9500.692Tang, Q. S.^[@CR27]^2014ChinaAsianBreast cancerHBTaqMan assay2395192129702804861689340.9380.692Zhang, Y. G.^[@CR41]^2014ChinaAsianESCCHBPCR-RFLP20518238494243182214940.8940.519Xu, X.^[@CR39]^2015ChinaAsianESCCHBTaqMan assay1864211734252293971384460.2570.692Lin, L.^[@CR40]^2015ChinaAsianColorectal cancerHBTaqMan assay2223381507802773511327640.0270.088Liu, N.^[@CR37]^2015ChinaAsianESCCHBPCR-RFLP173241802261452481012260.4400.988Zhang, J.^[@CR23]^2016ChinaAsianRenal cancerHBTaqMan assay173567102454267600.3110.253***AKT1*** **rs2494750GGGCCCTotalGGGCCCTotal**Cao, Q.^[@CR7]^2012ChinaAsianRenal cancerHBTaqMan assay30034070710349328837600.0620.652Chen, J. W.^[@CR15]^2012ChinaAsianProstate cancerHBTaqMan assay80269317666782993317080.0530.399Fallah, S^[@CR24]^2015IranAsianEndometrial cancerHBPCR-RFLP1965302253300.0070.015Zhang, J.^[@CR23]^2016ChinaAsianRenal cancerHBTaqMan assay30034070710349328837600.0620.652Wang, M. Y.^[@CR25]^2016ChinaAsianGastric cancerHBTaqMan assay493480126109954548711211440.5770.833Zhu, J. H.^[@CR26]^2016ChinaAsianESCCHBTaqMan assay555448114111752146011510960.0980.371***AKT1*** **rs2494752AAAGGGTotalAAAGGGTotal**Tang, Q. S.^[@CR27]^2014ChinaAsianBreast cancerHBTaqMan assay3005111599703314641399340.0170.253Wang, M. Y.^[@CR25]^2016ChinaAsianGastric cancerHBTaqMan assay5474549911006234309111440.7300.167Zhu, J. H.^[@CR26]^2016ChinaAsianESCCHBTaqMan assay6114238311175974158410960.4090.317HB, Hospital based; PB, Population based; PCR-RFLP, polymorphism chain reaction- restriction fragment length polymorphism; ALL, Acute lymphocytic leukemia; ESCC, Esophageal squamous cell carcinoma; AML, Acute myeloid leukemia.

Meta-analysis results {#Sec7}
---------------------

### mTOR rs2295080, rs2536 and cancer risk analysis {#Sec8}

The meta-analysis results for the *mTOR* rs2295080 and rs2536 polymorphism and cancer susceptibility are illustrated in Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}, and Figure [S1](#MOESM1){ref-type="media"}. Overall, we observed that carrying *mTOR* rs2295080 TG or GG genotype and GG/TG genotype showed significant association with decreased cancer risk \[TG vs.TT in heterozygote model: OR(95% CI) = 0.82(0.76, 0.89), *P* \< 0.001; GG/TG vs. TT in dominant model: OR(95% CI) = 0.82(0.76, 0.88), *P* \< 0.001; and GG vs.TG/TT in recessive model: OR(95% CI) = 0.67(0.51, 0.88), *P* = 0.004\]. In view of the relative higher heterogeneities, we further analyzed the data by stratification subgroups of urinary system cancer, blood system cancer, and digestive system cancer. Subsequently, we found that rs2295080 GG genotype, TG genotype, and GG/TG genotypes carriers showed a significantly decreased cancer risk in the stratification analysis of urinary system cancer \[GG vs.TT: OR(95% CI) = 0.78(0.62, 0.97), *P* = 0.029; TG vs. TT: OR(95% CI) = 0.77(0.69, 0.85), *P* \< 0.001; GG/TG vs. TT: OR(95% CI) = 0.77(0.69, 0.85), *P* \< 0.001; and GG vs. TG/TT: OR(95% CI) = 0.79(0.63, 0.98), *P* = 0.035\] and digestive system cancer \[GG vs.TT: OR(95% CI) = 0.56(0.40, 0.79), *P* = 0.001; TG vs. TT: OR(95% CI) = 0.81(0.70, 0.94), *P* = 0.006; GG/TG vs. TT: OR(95% CI) = 0.77(0.67, 0.89), *P* = 0.001; and GG vs. TG/TT: OR(95% CI) = 0.55(0.40, 0.77), *P* = 0.001\]. However, in the subgroup analysis of blood system cancer, inversely results were found that a significantly increased cancer risk was observed in the carriers of GG genotype \[GG vs.TT: OR(95% CI) = 2.25(1.33, 3.82), *P* = 0.003\]. For *mTOR* rs2536 polymorphism, there was no association was observed both in overall analysis and subgroup analysis (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}).Table 2Meta-analysis of the association between genetic polymorphisms of PTEN/AKT/mTOR pathway and cancer risk.VariablesNo. of cases/controls*P* ^z\*^Homozygous OR(95% CI)*P* ^het\#^*I* ^2\#^ (%)*P* ^z^\*Heterozygous OR(95% CI)*P* ^het\#^*I* ^2\#^ (%)***mTOR*** **rs2295080GG vs. TTTG vs. TT**Urinary system cancer^†^4203/4392**0.0290.78(0.62, 0.97)**0.9780.0**0.0000.77(0.69, 0.85)**0.9990.0Blood system cancer^§^5971/1146**0.0032.25(1.33, 3.82)**0.26424.80.5741.07(0.86, 1.33)0.6910.0Digestive system cancer^¶^3605/3747**0.0010.56(0.40, 0.79)**0.4810.0**0.0060.81(0.70, 0.94)**0.7070.0**Overall**8965/98680.4560.89(0.65, 1.22)0.00169.2**0.0000.82(0.76, 0.89)**0.4650.0***mTOR*** **rs2536CC vs. TTTC vs. TT**Urinary system cancer3090/32790.9541.02(0.56, 1.86)0.9760.00.7290.95(0.69, 1.29)0.00181.0Digestive system cancer417/5540.9750.99(0.64, 1.53)0.970.00.4731.04(0.93, 1.17)0.7890.0Blood system cancer4344/44210.1812.59(0.64, 10.43)------0.2450.82(0.58, 1.15)------**Overall**8411/88370.5551.10(0.80, 1.53)0.9680.00.9981.00(0.89, 1.13)0.02253.7***pTEN*** **rs701848CC vs. TTTC vs. TT**Oral cavity cancer^¥^331/3560.3590.81(0.53, 1.26)0.31216.00.2920.82(0.57, 1.18)0.6030.0Digestive system cancer2418/2662**0.0001.51(1.24, 1.84)**0.03757.7**0.0001.36(1.19, 1.57)**0.03259.2Urinary system cancer2086/2228**0.0011.33(1.12, 1.58)**0.5610.0**0.0491.14(1.00, 1.31)**0.5390.0**Overall**5882/6284**0.0001.35(1.21, 1.51)**0.01948.1**0.0001.21(1.11, 1.32)**0.05040.9***AKT1*** **rs2494750CC vs. GGGC vs. GG**Urinary system cancer2086/22280.8300.97(0.76, 1.24)0.6710.00.0503.60(1.00, 12.97)0.00096.0Reproductive system cancer^\$^30/300.6210.93(0.70, 1.24)------00.01(0.01, 0.03)------Digestive system cancer2216/22400.2641.13(0.91, 1.41)0.3045.30.2921.31(0.79, 2.17)0.00097.5**Overall**4332/44980.7271.03(0.89, 1.18)0.6580.00.9431.03(0.49, 2.17)0.00097.5***AKT1*** **rs2494752GG vs. AAAG vs. AA**Digestive system cancer2217/22400.3971.10(0.88, 1.38)0.27316.80.1511.10(0.97, 1.24)0.13754.8Other cancer970/9340.0981.26(0.96, 1.66)------0.0571.22 (0.99, 1.48)------**Overall**3187/31740.0901.16(0.96, 1.38)0.4120.0**0.0261.13(1.01, 1.25)**0.22832.4^\*^ *P* ^z^: the significance of the pooled OR was determined by Z-test, and *P* \< 0.05 was considered as statistically significant.^\#^ *P* ^het^ and *I* ^2^ were calculated by Chi square-based Q-test.^†^Urinary system cancer: renal cancer, prostate cancer; ^§^Blood system cancer: acute lymphocytic leukemia, acute myeloid leukemia; ^¶^Digestive system cancer: gastric cancer, ESCC, hepatocellular cancer, colorectal cancer; ^¥^Oral cavity cancer: laryngo cancer; ^\$^Reproductive system cancer: endometrial cancer. Table 3Meta-analysis of the association between genetic polymorphisms of PTEN/AKT/mTOR pathway and cancer risk by recessive and dominant models.Variables*P* ^z\*^Dominant OR(95% CI)*P* ^het\#^*I* ^2\#^ (%)*P* ^z\*^Recessive OR(95% CI)*P* ^het\#^*I* ^2\#^ (%)***mTOR*** **rs2295080GG/TG vs. TTGG vs. TG/TT**Urinary system cancer^†^**0.0000.77(0.69, 0.85)**1.0000.0**0.035**0.79(0.63, 0.98)0.8270.0Blood system cancer^§^0.1421.17(0.95, 1.44)0.7220.00.7420.91(0.52, 1.59)0.13949.3Digestive system cancer^¶^0.0010.77(0.67, 0.89)0.8670.0**0.001**0.55(0.40, 0.77)0.8090.0**Overall0.0000.82(0.76, 0.88)**0.11336.9**0.004**0.67(0.51, 0.88)0.00467.2*mTOR* rs2536CC/TC vs. TTCC vs. TC/TTUrinary system cancer0.8360.99(0.86, 1.13)0.00279.30.9721.01(0.55, 1.85)0.9520.0Digestive system cancer0.4891.04(0.93, 1.16)0.7490.00.9600.99(0.64, 1.53)0.9760.0Blood system cancer0.4000.87(0.62, 1.21)------0.1652.68(0.67, 10.78)------**Overall**0.6491.02(0.94, 1.10)0.03649.70.5721.10(0.79, 1.53)0.9610.0***pTEN*** **rs701848CC/TC vs. TTCC vs. TC/TT**Oral cavity cancer^¥^0.6740.82(0.58, 1.15)0.5680.00.2500.92(0.64, 1.34)0.4090.0Digestive system cancer**0.017**1.40(1.22, 1.59)0.06152.5**0.0001.23(1.04, 1.47)**0.02760.4Urinary system cancer**0.008**1.20(1.05, 1.36)0.7840.0**0.0061.23(1.05, 1.43)**0.4760.0**Overall0.000**1.25(1.15, 1.36)0.17924.9**0.0001.20(1.09, 1.32)**0.01549.9***AKT1*** **rs2494750CC/GC vs. GGCC vs. GC/GG**Urinary system cancer0.3101.09(0.92, 1.30)0.3690.00.9991.00(0.84, 1.20)0.5750.0Reproductive system cancer^\$^0.3120.92(0.78, 1.08)------0.8250.97(0.74, 1.28)------Digestive system cancer0.0551.13(1.00, 1.29)0.7840.00.5571.07(0.86, 1.31)0.18543**Overall**0.1981.06(0.97, 1.16)0.29318.50.8101.02(0.90, 1.15)0.670.0***AKT1*** **rs2494752GG/AG vs. AAGG vs. AG/AA**Digestive system cancer0.1291.10(0.97, 1.23)0.09863.50.6141.06(0.85, 1.31)0.4470.0Other cancer0.0371.23(1.01, 1.48)------0.3651.12(0.88, 1.44)------**Overall**0.0171.13(1.02, 1.25)0.15746.00.3291.08(0.92, 1.28)0.7040.0^\*^ *P* ^z^: the significance of the pooled OR was determined by *Z*-test, and *P* \< 0.05 was considered as statistically significant.^\#^ *P* ^het^ and *I* ^2^ were calculated by Chi square-based Q-test.^†^Urinary system cancer: renal cancer, prostate cancer; ^§^Blood system cancer: acute lymphocytic leukemia, acute myeloid leukemia; ^¶^Digestive system cancer: gastric cancer, ESCC, hepatocellular cancer, colorectal cancer; ^¥^Oral cavity cancer: laryngo cancer; ^\$^Reproductive system cancer: endometrial cancer. Figure 2Forest plots of cancer risk with polymorphism of *mTOR* rs2529080 (**A,B**), *pTEN* rs701848 (**C,D**) and *AKT1* rs2494752 (**E,F**) assessing by subgroup analysis under the homozygoute model (**A,C,E**), heterozygote model (**B,D,F**). The estimates of OR(95% CIs) are plotted with a box and a horizontal line for each study. ◇, pooled ORs (95% CIs).

### pTEN rs701848 and cancer risk analysis {#Sec9}

The effect of *pTEN* rs701848 polymorphism on cancer risk in overall and subgroup analysis was shown in Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and Figs [3](#Fig3){ref-type="fig"} and [S2](#MOESM1){ref-type="media"}.The SNP rs701848 CC or TC genotype and CC/TC genotype were associated with an increased overall cancer risk \[CC vs.TT in homozygote model: OR(95% CI) = 1.35(1.21, 1.51), *P* \< 0.001; TC vs. TT in heterozygote model: OR(95% CI) = 1.21(1.11, 1.32), *P* \< 0.001; CC/TC vs. TT in dominant model: OR(95% CI) = 1.25(1.15, 1.36), *P* \< 0.001; and CC vs. TC/TT in recessive model: OR(95% CI) = 1.20(1.09, 1.32), *P* \< 0.001\]. In the further stratification analysis, we found that rs701848 CC genotype, TC genotype and CC/TC genotypes were statistically increased association with digestive system cancer \[CC vs.TT: OR(95% CI) = 1.51(1.24, 1.84), *P* \< 0.001; TC vs. TT: OR(95% CI) = 1.36(1.19, 1.57), *P* \< 0.001; and CC/TC vs. TT: OR(95% CI) = 1.40(1.22, 1.59), *P* = 0.017; and CC vs. TC/TT: OR(95% CI) = 1.23(1.04, 1.47), *P* \< 0.001\] and urinary system cancer\[CC vs. TT: OR(95% CI) = 1.33(1.12, 1.58), *P* \< 0.001; TC vs. TT: OR(95% CI) = 1.14(1.00, 1.31), *P* = 0.049; and CC/TC vs. TT: OR(95% CI) = 1.20(1.05, 1.36), *P* = 0.008; and CC vs. TC/TT: OR(95% CI) = 1.23(1.05, 1.43), *P* = 0.006\], however no association was observed between the oral cavity cancer and cancer risk in this concluded studies.Figure 3Forest plots of cancer risk with polymorphism of *mTOR* rs2529080 (**A,B**), *pTEN* rs701848 (**C,D**) and *AKT1* rs2494752 (**E,F**) assessing by subgroup analysis under the dominant model (**A,C,E**) and recessive model (**B,D,F**). The estimates of OR(95% CIs) are plotted with a box and a horizontal line for each study. ◇, pooled ORs (95% CIs).

AKT1 rs2494750, rs2494752 and cancer risk analysis {#Sec10}
--------------------------------------------------

The association between polymorphisms of *AKT1* rs2494750, rs2494752 and cancer risk in overall meta-analysis results was shown in Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}, and Figure [S2](#MOESM1){ref-type="media"}. A significant association was observed between *AKT1* rs2494752 and overall cancer risk, and the heterozygous genotype AG and GG/AG genotype of *AKT1* rs2494752 were associated with increased cancer risk (AG vs. AA in heterozygote model: OR(95% CI) = 1.13(1.01, 1.25), *P* = 0.026; and GG/AG vs. AA in dominant model: OR(95% CI) = 1.13(1.02, 1.25), *P* = 0.017). For *AKT1* rs2494750 polymorphism, we have not found the correlation with the cancer susceptibility both in overall analysis and subgroup analysis (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}).

Heterogeneity and sensitivity analysis {#Sec11}
--------------------------------------

No significant heterogeneities were observed for the overall analyses of *mTOR* rs2536, *AKT1* rs2494750 and rs2494752. However, the highest heterogeneity were observed when all the studies were analyzed for all the cases of *mTOR* rs2295080 under the dominant model (*I* ^2^ = 96.1%) and *pTEN* rs701848 under the dominant model (*I* ^2^ = 62.0%) (Tables [S1](#MOESM1){ref-type="media"} and [S2](#MOESM1){ref-type="media"}). The heterogeneity of *mTOR* rs2295080 was also present in the subgroup of urinary system cancer and digestive system cancer under the dominant model (Table [S2](#MOESM1){ref-type="media"}). Therefore, the leave-one-out sensitivity analysis and random-effects model was selected for decreasing the heterogeneity. When these 3 publications of Zhu, M. L. (2015), Wang, M.Y. (2015), Zhu, J.H. (2015) were deleted, the value of *I* ^2^ decreased from 96.1% to 39.6% under the dominant model. More importantly, after deleting these 2 articles of Zhu, M. L. (2015), Wang, M.Y. (2015) from digestive system cancer, the subgroup of heterogeneity significantly decreased from 97.6% to 0% (Tables [3](#Tab3){ref-type="table"} and [S2](#MOESM1){ref-type="media"}). Another article of Zhu, J.H. (2015) from urinary system cancer was deleted, the *I* ^2^ decreased from 96.3% to 0% under the dominant model in subgroup analysis (Tables [3](#Tab3){ref-type="table"} and [S2](#MOESM1){ref-type="media"}). For *pTEN* rs701848, we found that the heterogeneity of overall and subgroup was significantly decreased after deleting this article of Zhang Y.G.(2014), except the subgroup under the digestive system cancer (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [S1](#MOESM1){ref-type="media"} and [S2](#MOESM1){ref-type="media"}).

Publication bias analysis {#Sec12}
-------------------------

In this meta-analysis, the Begg's funnel plot and Egger's test were performed to evaluate the publication bias of the concluded studies. There are no significant publication bias was observed for all the dominant models of the five SNPs (rs2295080: *P* = 0.200; rs2536: *P* = 0.176; rs701848: *P* = 0.218; rs2494750: *P* = 0.694 and rs2494752: *P* = 0.696) by the Egger's test. The funnel plots shapes showed obvious symmetry, which were obtained for the association of the SNPs under the dominant model (rs2295080: *P* = 0.672; rs2536: *P* = 0.531; rs701848: *P* = 0.373; rs2494750: *P* = 1.000 and rs2494752: *P* = 602) (Fig. [4](#Fig4){ref-type="fig"}). The data indicated that no publication bias might have a significant influence on the observed effect of SNPs located at pTEN/AKT/mTOR pathway on the susceptibility of cancer as assessed.Figure 4Begg's funnel plots to detect publication bias with pseudo 95% CIs under the dominant model. Each point represents an independent study for the indicated association. (**A**) *mTOR* rs2295080; (**B**) *mTOR* rs2536; (**C**) *pTEN* rs701848; (**D** and **E**) *AKT1* rs2494750 and rs2494752.

Discussion {#Sec13}
==========

Overexpression or mutations of key genes of the pTEN/AKT/mTOR pathways were associated with carcinogenesis, invasion, metastasis, and prognosis of a variety of cancers^[@CR44],[@CR45]^. Since one group investigated the association of genetic polymorphisms of the pTEN/AKT/mTOR pathway with cancer risk for the first time^[@CR31]^, a variety of studies have been performed to explore the possible correlation of the SNPs in this pathway genes on cancer susceptibility^[@CR6]--[@CR9],[@CR15]--[@CR23],[@CR28]--[@CR42]^. The potentially functional SNPs in those key genes, especially in the TFBS or miRNA binding sites may involve in the cancer susceptibility. Therefore, the present meta-analysis analyzed the associations of SNPs in the 5′upstream regulatory or promoter region (*mTOR* rs2295080, *AKT1* rs2494752), and 3′UTR region (*mTOR* rs2536, *pTEN* rs701848 and *AKT1* rs2494750) in the mTOR signaling pathway (*AKT*, and *PTEN*) with cancer risk.

mTOR rs2295080 and rs2536 SNPs and cancer risk {#Sec14}
----------------------------------------------

Given the crucial function of *mTOR* in cellular signals from growth factors and energy status, such as in angiogenesis and cell proliferation, growth, differentiation, and apoptosis^[@CR3]--[@CR5],[@CR44],[@CR45]^, our findings of an association between the genetic variations in *mTOR* gene and cancer risk are biologically plausible and wide, including renal cell cancer^[@CR7],[@CR21],[@CR23]^, prostate cancer^[@CR15],[@CR17]^, breast cancer^[@CR22]^, acute lymphocytic leukemia^[@CR16],[@CR20]^, gastric cancer^[@CR19],[@CR29]^, esophageal squamous cell cancer^[@CR18]^, hepatocellular cancer^[@CR23],[@CR28]^ and colorectal cancer^[@CR8]^. In this meta-analysis of 13 studies including 8965 cases and 9868 controls for rs2295080, we found a significant decreased of rs2295080 TG, GG genotype, G allele and TG/GG genotype on the overall cancer risk, and the stratification subtype of urinary system cancer and digestive system cancer. However, a significant increased association was found on the blood system cancer in the homozygous GG genotype and G allele under the subgroup analysis. Up to now, only two meta-analyses focused on *mTOR* rs2295080 polymorphism and cancer risk^[@CR46],[@CR47]^. In one meta-analysis reported that the rs2295080 G allele is associated with decreased risk of cancer^[@CR46]^, however, only five studies were included. Recent some opposite findings were reported in gastric cancer^[@CR6]^, esophageal cancer^[@CR18]^, and especially in acute leukemia^[@CR16],[@CR20]^. Thereafter, another eight studies meta-analysis found that the rs2295080 G allele was associated with a significantly lower risk of genitourinary cancers in the dominant model, and a higher risk of acute leukemia in the recessive model^[@CR47]^, which consistent with our founding's in overall cancer risk and digestive system cancer. Likewise, we further founded that carrying rs2295080 GG genotype showed increased 2.25-fold association in the blood system cancer including acute lymphocytic leukemia and acute lymphocytic leukemia which was not explicated in the previous meta-analyses. Thus, these data indicated that there was an obvious divergence between the SNP rs2295080 and cancer risk in the digestive system and blood system, which might be partially explained by cancer-specificity of rs2295080 polymorphism.

10 studied of 8411 cases and 8837 controls for rs2536 polymorphism, no significant association was observed between rs2536 and cancer susceptibility after performing stratified analyses by cancer type^[@CR7],[@CR15]--[@CR18],[@CR22],[@CR23],[@CR28]--[@CR30]^ in this pooled meta-analysis. Previously, Shao *et al*.^[@CR46]^ performed a six case-control studies meta-analysis and also reported that there was no association of rs2536 SNP with cancer risk both under dominant and recessive models. Furthermore, this present updated meta-analysis also indicated that rs2536 polymorphism was not an important biomarker for predicting cancer risk, although rs2536 was observed associated with the risk of esophageal cancer^[@CR18]^ and prostate cancer^[@CR15]^, together with interacting with environmental factors such as body mass index. The previous foundlings were controversial for the SNP rs2536, partially because of insufficient statistical power and further studies of different cancers are needed for providing a more precise estimation of the associations.

pTEN rs701848 and cancer risk {#Sec15}
-----------------------------

*pTEN* was originally identified as tumor suppressor gene, considered as a key negative regulator of PI3K/Akt pathway^[@CR48]--[@CR50]^. However, little is known about the association between *pTEN* rs701848 polymorphism and cancer. Specifically, 15 studies of 5882 cases and 6284 controls for rs701848, CC or TC genotype, C allele and CC/TC genotype were associated with significant increased overall cancer risk and in the subgroup of the digestive system cancer and urinary system cancer, but not in oral cavity cancers. Since Zou *et al*.^[@CR31]^ for the first time reported a significant association of *pTEN* rs701848 with laryngo cancer risk in 2006, more evidences have accumulated regarding the relationship between SNP rs701848 and the risk of various cancers, such as lung cancer^[@CR35]^, esophageal cancer^[@CR37]--[@CR39],[@CR41]^, breast cancer^[@CR27]^, prostate cancer^[@CR15]^, hepatocellular cancer^[@CR36]^, renal cancer^[@CR7],[@CR23]^, gastric cancer^[@CR42]^, and colorectal cancer^[@CR40]^. It should be noted that SNP rs701848 is located within the 3′ near gene region, which can be targeted by microRNAs to affecting the miRNA binding site activity, thereby altering pTEN expression by influencing the mRNA stability, and then influence cancer susceptibility. However, the hypothesized function about SNP rs701848 still needs to be investigated in future studies and updated meta-analysis.

AKT1 rs2494750, rs2494752 and cancer risk {#Sec16}
-----------------------------------------

In this pooled meta-analysis, 6 studied of 4332 cases and 4498 controls for rs2494750 polymorphism^[@CR7],[@CR15],[@CR23]--[@CR27]^ and 3 studied of 3187 cases and 3174 controls for rs2494752 polymorphism^[@CR19],[@CR26],[@CR27]^ were included. A significant association was observed between rs2494752 and overall cancer risk, the heterozygous genotype AG, GG/AG genotype and G allele of rs2494752 SNP was associated with increased cancer risk. However, we have not found the correlation between rs2494750 polymorphism and the cancer susceptibility both in overall analysis and the stratification analysis. Previous study reported^[@CR15]^ that the risk effect of rs2494752 AG/GG genotypes was more obvious in the patients of ever-drinkers. Another investigation showed inconsistent results in alcohol consumption patients and risk of gastric cancer^[@CR25]^. These results indicated that the environmental factors were interacted with the genetic variants in the aspect of carcinogenesis. Most importantly, the SNP rs2494752 is located at the 5′ UTR of *AKT1* gene, a region predicted to be the transcription factor binding region based on the sequence alignments, which may affect the transcription and translation of *AKT1*. It is plausible that the rs2494752 G allele increased the transcription activity of the promoter in the *AKT1* gene, then facilitated the cancer development and progression, which may partially explain the cancer risk associated with this SNP. However, the potential function of this SNP should be necessary to identify in larger sample studies in the future.

There is not previously reported meta-analysis to date that comprehensively elucidated the association between the five SNPs of the pTEN/AKT/mTOR signaling pathway and risk of cancer. However, some limitations need to be addressed in this meta-analysis. First, only Asian population was involved, lack of the samples of other ethnicities such as Caucasian, African in this study, thus a wider spectrum of subjects should be conducted on various ethnicities in the future. Second, only 3 studies were included for the SNP rs2494752, therefore considering the limited small size of rs2494752, we cannot rule out the possibility that the results may be by chance, although the number of study participants met the requirement for analysis. Third, all studies included in the present systematic review were reported in Chinese or English, yet other languages publications may include the relevant studies, which may be the main source of publication bias in our meta-analysis. Finally, only five SNPs located in the 3′UTR or 5′UTR of the candidate genes were chosen, however, the SNPs of exon or intron region was not included. Thus, the limited SNPs were not sufficient to capture most genetic information of pTEN/AKT/mTOR signaling pathway, more SNPs should be included in the study, and interaction with others genes should be investigated in the future updated meta-analysis.

In conclusion, this meta-analysis was performed included the latest publications, and provided a more precise prevalence estimate for associations of five SNPs of pTEN/AK/mTOR pathway with the risk of cancer. We found that *mTOR* rs2295080 TG, GG genotype and GG/TG genotype carriers showed an decreased in the overall cancer risk, urinary system cancer and digestive system cancer, nevertheless TT genotype of rs2295080 was associated with increased the risk of blood system cancer. Carrying rs701848 CC,TC genotype and CC/TC genotype were associated with an increased overall cancer risk, especially in digestive system cancer and urinary system cancer. Moreover, a significant increased association was observed between rs2494752 AG and GG/AG genotype and overall cancer risk. Therefore, this present study provides the most valid cancer prevalence estimate to date for Asian population, which is a necessary foundational piece for further research on this topic.

Novelty and Impact Statements {#Sec17}
-----------------------------

In this meta-analysis of Asian population, the carriers of *mTOR* rs2295080 TG, GG genotype and GG/TG genotypes showed a significantly decreased the risk of overall cancer, the urinary system cancer and digestive system cancer. Furthermore, the SNP rs701848 CC, TC genotype and CC/TC genotype of *pTEN* were observed increased susceptibility of overall cancer and the subgroup of the urinary and digestive cancer. Moreover, carrying *AKT1* rs2494752 AG and GG/AG genotypes showed an increased overall cancer risk.
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